The intracellular pathways for basal atrial natriuretic factor (ANF) secretion from the heart and their correlation with ANF processing to the active form were characterized in cultured neonatal rat atrial and ventricular myocytes. Brefeldin A, a fungal antimetabolite that blocks transport of newly synthesized proteins from the endoplasmic reticulum, was used to inhibit nascent protein trafficking. Thus, release of newly synthesized hormone was blocked, but release of stored hormone was unaffected. Whereas brefeldin A inhibited basal ventricular ANF release to 10% of the control value, basal ANF release from atrial cells was enhanced. Furthermore, basal atrial ANF secretion was inhibited by agents preventing myocyte depolarization, Ca2+ influx, release of Ca2+ from intracellular stores, or activation of protein kinase C, whereas ventricular ANF secretion was unaffected by these agents.
The intracellular pathways for basal atrial natriuretic factor (ANF) secretion from the heart and their correlation with ANF processing to the active form were characterized in cultured neonatal rat atrial and ventricular myocytes. Brefeldin A, a fungal antimetabolite that blocks transport of newly synthesized proteins from the endoplasmic reticulum, was used to inhibit nascent protein trafficking. Thus, release of newly synthesized hormone was blocked, but release of stored hormone was unaffected. Whereas brefeldin A inhibited basal ventricular ANF release to 10% of the control value, basal ANF release from atrial cells was enhanced. Furthermore, basal atrial ANF secretion was inhibited by agents preventing myocyte depolarization, Ca2+ influx, release of Ca2+ from intracellular stores, or activation of protein kinase C, whereas ventricular ANF secretion was unaffected by these agents.
A trial natriuretic factor (ANF) is a hormone secreted by the atrium, which regulates blood volume and blood pressure by stimulating receptors located in the kidney, adrenal gland, vascular smooth muscle, and discrete regions of the brain to cause diuresis, natriuresis, and vascular relaxation.1,2 ANF biosynthesis is similar to that of other peptide hormones, since ANF is stored in secretory granules and its release can be stimulated by appropriate secretagogues.3 However, whereas the primary physiological stimulus for ANF secretion is atrial stretch caused by volume expansion, ANF is also secreted continually, even under basal conditions. This constant basal secretion of ANF has been demonstrated both in vivo and in vitro. In primary cultures of rat atrial myocytes, the basal secretion rate of ANF per hour represents :10% of the total cell ANF content.
In the present study, we investigated the cellular mechanisms underlying basal ANF secretion in cultured neonatal atrial myocytes. It is possible that this basal secretion is derived from the constitutive pathway of protein secretion, whereas stimulated ANF secretion originates from the triggered release of secretory granules. Dual mechanisms of secretion have been observed in endocrine cells such as the AtT20 pituitary cell line. 4 Alternatively, basal ANF secretion may represent ANF secretory granule exocytosis stimulated by spontaneous spikes in intracellular Ca21 levels associated with myocyte contraction.
Resolution of the ANF secretory pathways used by atrial cells is also necessary to clarify the relative location of pro-ANF [ANF- ] processing to the active form ]. Although atrial myocytes cosecretionally cleave ANF to the correct circulating forms, processing is only 70% to 80% complete.5 Since maturational processing generally correlates with secretion via the regulated pathway, incomplete ANF processing by atrial myocytes could indicate that a portion of ANF is being secreted via a constitutive pathway that lacks a processing enzyme. Because an ANF processing enzyme has been isolated from bovine atrial granules,6 it is feasible that ANF processing is pathway specific. Lack of correlation of ANF processing with the regulated secretory pathway may reflect the existence of a novel cardiac-specific processing mechanism.
A parallel study of ANF secretion from neonatal ventricular myocytes was also undertaken because of recent questions raised regarding the secretory mechanisms in this cell type. That is, ventricular ANF secretion was originally believed to be primarily constitutive; this belief was based on the lack of secretory granules in this tissue7 and the inability to stimulate ANF secretion to levels above those observed basally. For identification of newly synthesized proteins, the myocytes were metabolically labeled with [35S] cysteine. This procedure allowed brefeldin A activity to be detected as a reduction in release of 35S-labeled proteins into the cell medium, which results from the trapping of newly synthesized proteins in the endoplasmic reticulum-Golgi composite produced by brefeldin A. 10-1L aliquot of undiluted antiserum with 40 gg protein A-sepharose in 0.5 mL of "radioimmunoassay buffer" (50 mmol/L NaCI, 0.1% Triton X-100, 0.1% BSA, and 100 mmol/L phosphate, pH 7.4) for 2 hours on ice. After sedimentation of the complex (500g, 5 minutes) and resuspension in the same volume of medium, 0.5 mL of ANF-containing secretion medium or cell lysate was combined with the preformed immune complex. This mixture was incubated overnight at 5°C, followed by sedimentation (5O0g, 5 minutes) and then resuspension of the pellet with lysis buffer. After centrifugation (500g), the final immunoprecipitated complexes were analyzed by electrophoresis (see below). There are only two cysteines in the entire pro-ANF molecule, which are located at C-terminal residues 105 and 121. Thus, the pro-ANF and mature ANF forms will have the same number of labeled cysteines.
In some experiments, total 35S-labeled proteins released into the secretion medium and those remaining in the cells were examined. This was accomplished either by direct electrophoresis of 50 to 100 pL of cell secretion medium or cell lysate (Fig) To quantify the observed effect of brefeldin A, 35S-labeled proteins in both the culture medium and cells were precipitated with TCA and counted for radioactivity. As shown in Table 1 , this method again demonstrated that total secretion of 35S-labeled protein was significantly reduced by brefeldin A treatment. However, this was associated with a small change in apparent protein synthesis. Brefeldin A decreased the incorporation of 'S into total cellular protein by 22+3% (mean+SEM, n=4, P<.O1). This observation is consistent with the results of a previous study showing that effective doses of brefeldin A produced a small decrease in 35S-labeled total protein. 22 In the previous study, a dose of 10 ,ug/mL brefeldin A decreased apparent protein synthesis in cultured rat hepatocytes by 26%. The effects of brefeldin A treatment specifically on ANF biosynthesis and secretion were similar to the effects on total protein synthesis and release. Brefeldin A markedly reduced the amount of immunoprecipitable 35S-labeled ANF secreted into the culture medium (panel C). This was associated with a small but significant decrease in the total ANF content of myocyte culture wells (19+3%, mean±SEM, n=6, P<.01) as measured by radioimmunoassay. It was also observed that inhibition of ANF secretion was partially reversed on removal of the drug (panel C).
One possible explanation for the incomplete reversal of brefeldin A action, as well as its effect on protein synthesis, is that the proteins trapped in the endoplasmic reticulum are partially degraded over time. This is consistent with our observation that more 35S-labeled proteins migrated with the dye front on SDS-PAGE gels of brefeldin A-treated samples compared with untreated control samples. Nevertheless, the small effect of brefeldin A on total myocyte protein content is insufficient to account for the observed changes in secretion. Therefore, our results are consistent with the proposed mechanism of action of brefeldin A, which is to block trafficking of nascent proteins.
ANF Secretory Pathways
The effects of brefeldin A on total ANF secretion from atrial and ventricular cells were determined by radioimmunoassay and are shown in Table 1 . Under control conditions, : 14% of total atrial ANF was secreted into the medium in 1 hour. Ventricular cells secreted =38% of their total ANF per hour, revealing less hormone storage. In the presence of brefeldin A, ventricular secretion was markedly reduced; however, no inhibition of atrial secretion was observed. In fact, in 10 experiments performed on atrial cells, ANF secretion was increased to 146±50% of the control (mean+SD, P<.01) by the addition of brefeldin A, although reduced release of 35S-labeled proteins in the same cell wells verified blockade of protein trafficking. However, the extent of this enhancement was variable, leading to less significance in small data pools (as seen in Table 1 ). that the agents are acting incompletely or that a small fraction of ANF release via granules is unregulated but not due to constitutive ANF secretion.
In parallel experiments, the same agents were added to ventricular cells, and neither EGTA, pinacidil, staurosporine, nor these agents added in combination decreased ANF secretion significantly. Thus, the secretory pathway used for release of ventricular ANF is not regulated by the intracellular signals important to atrial ANF secretion. Correlation of Pro-ANF Processing and the
Secretory Pathway
As shown in Table 3 , 70% to 80% of atrial and ventricular myocyte ANF is secreted as the processed mature form of the hormone, ie, ANF-(99-126). This was determined both by SDS-PAGE (Figure) and by HPLC analyses of the culture medium (see "Materials and Methods"). Atrial ANF processing was unaffected by the addition of brefeldin A or by stimulation of secretion by endothelin (Table 3) . These findings suggest that both basal and "stimulated" ANF secretion from atrial cells are derived from the same secretory pathway. The ANF processing of ventricular myocytes was not significantly different from atrial processing, even when total secretion was inhibited to 10% by brefeldin A, suggesting that pro-ANF processing does not require passage through the regulated pathway. Ventricular processing of pro-ANF has also been observed by Glembotski et al.5, 12 There was no evidence of pro-ANF processing by the culture medium itself or by any other cell types in the culture. When trace amounts of exogenously added 35S-labeled pro-ANF were added to either atrial or ventricular culture wells, no significant cleavage was observed despite normal cleavage of endogenously produced ANF (data not shown). Also, addition of a cocktail of protease inhibitors to the secretion medium (,ug/mL: PMSF, 1.7; leupeptin, 1; bacitracin, 1; and Neonatal atrial myocytes undergo changes in culture over time. This is predominantly due to a redifferentiation process that occurs after cell dispersion with trypsin and reattachment to the culture dish, which is somewhat dependent on the composition of the culture media. At up to 5 days in culture, ANF release from atrial cells cannot be stimulated by secretagogues such as KCI or endothelin, and total cellular ANF content is low.1718 Thus, it is possible that a switch from the constitutive to regulated secretory pathway occurs as atrial cells redifferentiate. The existence of this mechanism was explored using brefeldin A.
After 60 hours in culture, atrial myocytes were observed to be morphologically different from cells cultured for 2 to 3 weeks. At this "early" time, myocytes had attached to the dish and resembled spindles but were visible as individual quiescent cells. In addition, endothelin had no effect on ANF secretion from atrial myocytes (ANF release was 103% of the control value), and ANF processing to the active form was minimal [11±2% of released ANF was in the ANF-(99-126) form, n=2]. These results confirm earlier observations by Shields et al5 and Sei and Glembotski.17 However, as demonstrated in Table 4 , brefeldin A did not inhibit cellular secretion, indicating no constitutive secretion of ANF. In these nonbeating cells, the predominant mechanism of basal ANF secretion is apparently protein kinase C-mediated, since neither cell hyperpolarization by pinacidil nor chelation of extracellular Ca 2' by EGTA significantly inhibited secretion (Table 4) . This finding contrasts with the results obtained with atrial myocytes maintained in culture for 3 weeks ( During the course of the present study, others have confirmed that neonatal ventricular cells possess no dense-cored storage granules and release newly synthesized ANF rapidly, yet they have also observed that endothelin transiently stimulates ventricular secretion. 9 We have been unable to demonstrate endothelin-stimulated ANF secretion from ventricular cells, suggesting that it may depend on experimental conditions. If confirmed, the observation may lead to the identification of a novel secretory pathway that is perhaps unique to neonatal ventricular myocytes: regulated release of "constitutive" secretory vesicles.
The enhancement of regulated secretion in atrial myocytes by brefeldin A was a surprising finding. Although this has also been observed in isolated atria,21 it has not been reported with the use of brefeldin A in other endocrine tissues. In fact, brefeldin A inhibits the formation of immature secretory granules at the transGolgi network. 29, 30 It is well established that brefeldin A has multiple effects on vesicular transport. Effects at the level of the Golgi apparatus are thought to be mediated by loss of /6-COP, a coat protein complex believed to be important in the segregation of intracellular membranes. Changes in the association of coat proteins with membranes may also be responsible for the inhibition of transcytotic vesicle formation observed with brefeldin A.13.'4 However, it is difficult to envision how this mechanism could specifically increase only regulated ANF secretion. Another possibility is suggested by the work of Zizi et al. 31 They have reported that brefeldin A acts as an ionophore, increasing K' and Na+ transport when added to planar lipid bilayers at a concentration of 1 ,ug/mL. This may increase the osmotic stress on granule membranes, making them more prone to lysis. Increased Na+ influx may also directly stimulate secretion by depolarizing the cells or may increase cellular [Ca'+] via Na+-Ca2' exchange.
The brefeldin A-induced increase in atrial ANF secretion complicated determination of whether there was a small constitutive component to atrial ANF secretion. It would be possible that a decrease in constitutive atrial secretion could be masked by an increase in regulated secretion. Thus, the results of adding signaling inhibitors (Table 2 ) were important to show that atrial secretion is primarily a regulated process. The inhibition of atrial secretion by agents that affect cell depolarization, Ca 2 influx, and protein kinase C support the idea that atrial release of ANF should be continuous from a regulated pathway because of the cyclic generation of second-messenger signals in a beating heart. This idea is supported by a recent study demonstrating that rhythmic exocytosis paralleled secretagogue-induced Ca 2 oscillations in single cells of rat gonadotropes. 32 An additional insight from the signaling study is the role of protein kinase C in basal ANF secretion from both long-term (21-day) and short-term (3-day) cultures of neonatal myocytes. This suggests that protein kinase C may be activated to some extent in normal beating cells. The data in Table 2 Brefeldin A was also used to determine whether pro-ANF processing was correlated with the regulated secretory pathway, as it is in many endocrine cell types. The lack of correlation found is unusual, although pro-ANF processing to ANF-(99-126) in the heart has been shown to be unique in several ways. First, ANF in cardiac cells is stored as the prohormone, whereas granular processing of pro-ANF occurs in extracardiac tissues. 37, 38 Processing by atrial cells is believed to occur as ANF is secreted or in "transient processing vesi- cles."''8 Second, the small quantities of ANF found in other tissues are cleaved at different sites in the molecule compared with the heart.39 Based on the results obtained in this study, a remaining issue is how and where processing occurs. The two major possibilities are that there is one enzyme cleaving pro-ANF in both atrial and ventricular cells or that separate enzymes with common substrate specificity are associated with different secretory pathways. If there is a single enzyme, it may be localized near the plasma membrane in both cell types or may be capable of functioning in association with either regulated or constitutive secretory vesicles. The dependence of processing activity on the presence of glucocorticoids in both tissues5 is consistent with the hypothesis of a single enzyme. Alternatively, there may be atrium-and ventricle-specific pro-ANFprocessing enzymes forms analogous to, but not identical with, the newly discovered prohormone convertases (PC2 and PC3) and furin.40 These endoproteases all cleave at basic residues and can yield similar products, yet the prohormone convertases PC2 and PC3 are expressed exclusively in tissues with regulated pathways, whereas furin is widely expressed among many tissues and is likely associated with constitutive secretion.
The observation that ventricular cells process pro-ANF is of interest in interpreting data on ANF secretion from hypertrophied ventricle. Although normal adult ventricle expresses little ANF, the ventricle reverts to a more fetal phenotype during hypertrophy or congestive heart failure, and ANF biosynthesis and secretion resumes. 41 Additionally, there is a measurable increase in circulating pro-ANF that is physiologically inactive.42 It was previously supposed that the increase in unprocessed ANF was due to the increase in constitutive secretion from ventricle; this would be reasonable if the processing enzyme could function only in the secretory granule environment. However, we have demonstrated that the enzyme is active in association with the constitutive secretory pathway as well. Therefore, it is likely that the reduction in ANF processing found in patients with congestive heart failure is not simply a consequence of an increase in the constitutive release of ANF from the ventricle. Rather, it is most likely due either to a defect in the production or activity of the processing enzyme or to the release of ANF from damaged cells.
In summary, the present study confirms and further delineates several important characteristics of the cardiac ANF secretory system. First, neonatal atria and ventricles use different secretory mechanisms despite expression of the ANF gene by both cell types. No regulated ANF secretion from ventricle was shown, whereas atrial ANF secretion has no apparent constitutive component, even at early times in culture. Second, basal ANF secretion by the atria is regulated, in part, by the second-messenger signals found to be active in most neural or endocrine cells (Ca2 depolarization and protein kinase C), although in myocytes these signals may be associated with stretch activation. Cardiac differences in the expression of Ca>2 channels, Ca2-ATPases, and Ca>2 storage mechanisms seem to make little difference to the exocytotic machinery. Thus, the basal, or spontaneous, secretion observed in these in vitro experiments most likely reflects continuous release of ANF from a beating heart in vivo. Third, pro-ANF processing activity is observed whether pro-ANF is secreted from a constitutive or regulated pathway and may be impaired with hypertrophy.
